Loading
This study tests a PARP inhibitor; the registry reports that it is withdrawn.
The registry lists NCT07060365 as withdrawn, last updated 2026-04-03. Enrolment is 0 actual participants. Interventions: Saruparib. Primary measures include Number of participants with treatment-emergent adverse event (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation. The registry reason for stopping is: The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns. No results are posted in the registry; this does not exclude separate publications.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/